Celldex Therapeutics (CLDX) Free Cash Flow (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Free Cash Flow of -$67.2 million for Q1 2026, down 23.06% year-over-year from -$87.4 million in Q1 2025, and down 3.09% quarter-over-quarter from -$65.2 million in Q4 2025.
Celldex Therapeutics (CLDX) Free Cash Flow (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$67.2 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 23.06% year-over-year to -$67.2 million; the TTM figure through Mar 2026 stood at -$226.3 million (down 30.52% YoY), while the FY2025 annual figure was -$213.7 million, down 33.79% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$67.2 million, down from -$65.2 million in the prior quarter.
- The five-year high for Free Cash Flow was -$19.2 million in Q3 2023, with the low at -$67.2 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$33.2 million (2024), against an average of -$38.5 million.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow soared 46.11% in 2023, then plunged 191.81% in 2024.
- Celldex Therapeutics' Free Cash Flow stood at -$22.0 million in 2022, then tumbled by 50.93% to -$33.2 million in 2023, then decreased by 0.1% to -$33.2 million in 2024, then sank by 96.27% to -$65.2 million in 2025, then fell by 3.09% to -$67.2 million in 2026.
- Business Quant data shows CLDX's Free Cash Flow at -$67.2 million in Q1 2026, -$65.2 million in Q4 2025, and -$49.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -60.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.58 Mn |
| Jun 30, 2026 | -60.58 Mn |
| Mar 31, 2026 | -67.24 Mn |
| Mar 31, 2026 | -67.24 Mn |
| Dec 31, 2025 | -65.23 Mn |
| Dec 31, 2025 | -65.23 Mn |
| Sep 30, 2025 | -49.06 Mn |
| Sep 30, 2025 | -49.06 Mn |
| Jun 30, 2025 | -44.73 Mn |
| Jun 30, 2025 | -44.73 Mn |
| Mar 31, 2025 | -54.64 Mn |
| Mar 31, 2025 | -54.64 Mn |
| Dec 31, 2024 | -33.23 Mn |
| Dec 31, 2024 | -33.23 Mn |
| Sep 30, 2024 | -55.88 Mn |
| Sep 30, 2024 | -55.88 Mn |
| Jun 30, 2024 | -29.60 Mn |
| Jun 30, 2024 | -29.60 Mn |
| Mar 31, 2024 | -40.98 Mn |
| Mar 31, 2024 | -40.98 Mn |